Lindsey J. Anstine

Lindsey J. Anstine

Auto-generated profile, based on publicly available information

Lindsey J. Anstine

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri
Breast cancer subtypes and their phenotypes parallel different stages of the mammary epithelial cell developmental hierarchy. Discovering mechanisms that control lineage identity could provide novel avenues for mitigating disease progression. Here we report that the transcriptional corepressor TLE3 is a guardian of luminal cell fate in breast cancer and operates independently of the estrogen receptor. In luminal breast cancer, TLE3 actively repressed the gene-expression signature associated with highly aggressive basal-like breast cancers (BLBC). Moreover, maintenance of the luminal lineage depended on the appropriate localization of TLE3 to its transcriptional targets, a process mediated by interactions with FOXA1. By repressing genes that drive BLBC phenotypes, including SOX9 and TGFβ2, TLE3 prevented the acquisition of a hybrid epithelial–mesenchymal state and reduced metastatic capacity and aggressive cellular behaviors. These results establish TLE3 as an essential transcriptional repressor that sustains the more differentiated and less metastatic nature of luminal breast cancers. Approaches to induce TLE3 expression could promote the acquisition of less aggressive, more treatable disease states to extend patient survival. Significance: Transcriptional corepressor TLE3 actively suppresses SOX9 and TGFβ transcriptional programs to sustain the luminal lineage identity of breast cancer cells and to inhibit metastatic progression.

4 April 2023
Verified
Other
Open access
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri



4 April 2023
Verified
Other
Open access
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri

4 April 2023
Verified
Other
Open access
LALindsey J. Anstine
Lindsey J. Anstine
PMParth R. Majmudar
Parth R. Majmudar
AAAmy Aponte
Amy Aponte
Salendra SinghSalendra Singh
Salendra Singh
RZRan Zhao
Ran Zhao
RKRuth Keri
Ruth Keri